Results 201 to 210 of about 113,104 (262)
Summary Single‐arm studies demonstrate dramatic improvements in survival in patients with relapsed/refractory (R/R) aggressive B‐cell lymphomas but with significant toxicities and at exceptionally high costs. The objective of this study was to evaluate the real‐world health outcomes of aggressive B‐cell lymphoma patients treated with publicly funded ...
Pierre J. A. Villeneuve +17 more
wiley +1 more source
A Comprehensive Evaluation of CAR-T Cell Gene Therapy, Tracing its Revolutionary Clinical Breakthroughs and Advancements Towards Next-Generation Engineering. [PDF]
Aliciaslan M, Erbasan E, Sanlioglu S.
europepmc +1 more source
Summary Secondary central nervous system lymphoma (SCNSL) remains a rare but challenging manifestation of aggressive lymphomas, with limited prospective data to guide treatment decisions in the modern therapeutic era. We conducted a multicentre retrospective cohort study of 105 consecutively treated adult patients diagnosed with SCNSL between 2016 and ...
Farina Eigendorff +10 more
wiley +1 more source
Pancreatic cancer induces B cell lineage plasticity via Pax5 inhibition to sustain immunosuppression. [PDF]
Kassem A +15 more
europepmc +1 more source
Summary Chronic lymphocytic leukaemia (CLL) presents a complex biological and clinical landscape, strongly influenced by the tumour microenvironment (TME). To better capture this heterogeneity, we have developed patient‐derived lymphoma spheroids from CLL samples (CLL‐PDLS), which recapitulate the cross‐talk between malignant cells and the autologous ...
Heribert Playa‐Albinyana +9 more
wiley +1 more source
Influence of B cell-lineage targeted CAR-T cell therapy on humoral immunity and vaccine-induced antibody response. [PDF]
Ozog S +20 more
europepmc +1 more source
Graphical overview of the network meta‐analysis (NMA) evaluating chemo‐free approaches for relapsed/refractory follicular lymphoma (R/R FL). Epcoritamab plus rituximab (R2) achieved the highest cumulative ranking probability (SUCRA) across efficacy end‐points but increases the risk of predictable toxicity over anti‐CD20 monotherapy.
Daniele Caracciolo +14 more
wiley +1 more source
Machine Learning-Assisted Rapid Optical Imaging for Label-Free CAR T-Cell Detection in Whole Blood. [PDF]
Yu N +10 more
europepmc +1 more source
In this real‐world cohort of 231 patients receiving chimeric antigen receptor (CAR) T‐cell therapy, hepatotoxicity occurred in 58% of patients, predominantly as transient transaminase elevations, and was not associated with impaired 12‐month overall survival (adjusted hazard ratio [HR] 1.18, 95% confidence interval [CI] 0.71–1.94).
Julius Hollnberger +11 more
wiley +1 more source

